Management of acute kidney injury in tumor lysis syndrome: a narrative review.

Laura Zeppilli, Santo Morabito, Antonietta Gigante, Valentina Pistolesi

Abstract readReview

In one paragraph

Review in Internal and emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laura ZeppilliHemodialysis Unit, Department of Internal Medicine and Clinical Sciences, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Sapienza University of Rome, Viale del Policlinico, 155, 00161, Rome, Italy.ORCID 0000-0002-2990-7947

Santo MorabitoHemodialysis Unit, Department of Internal Medicine and Clinical Sciences, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Sapienza University of Rome, Viale del Policlinico, 155, 00161, Rome, Italy. santo.morabito@uniroma1.it.ORCID 0000-0002-4897-1602

Antonietta GiganteDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-2015-765X

Valentina PistolesiHemodialysis Unit, Department of Internal Medicine and Clinical Sciences, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Sapienza University of Rome, Viale del Policlinico, 155, 00161, Rome, Italy.ORCID 0000-0002-9720-9462

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor lysis syndrome (TLS) is a life-threatening condition due to the rapid release of tumor cell contents into the bloodstream usually induced by cytotoxic therapy. It is characterized by the rapid onset of severe metabolic derangements such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. If not promptly recognized and treated, TLS can lead to serious clinical complications including acute kidney injury (AKI), cardiac arrhythmias, seizures, hypotension, and death. In particular, the occurrence of AKI could cause a delay in the administration of chemotherapy, thus compromising the efficacy of the treatment and contributing to worsening patient's prognosis. In this condition, a multidisciplinary approach appears crucial to implement strategies aimed at timely managing TLS and preventing AKI to improve main patient outcomes.

Indexed as

Acute Kidney InjuryTumor Lysis SyndromeHumansAcute kidney injuryCancerHyperuricemiaTumor lysis syndrome

Identifiers

PMID40682741

DOI10.1007/s11739-025-04050-x

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.